Efficacy of abciximab induced platelet blockade using a rapid point of care assay

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 3, 1999, Pages 265-276

  Kereiakes, Dean J ^a   Mueller, Michele ^a   Howard, Wendy ^a   Lacock, Pam ^b   Anderson, Linda C ^a   Broderick, Thomas M ^c   Roth, Eli M ^c   Whang, David D ^c   Abbottsmith, Charles W ^c  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b Health Alliance Laboratory Service   (United States)

^c Ohio Heart and Vascular Center   (United States)

Author keywords

Abciximab; PC RPFA; Platelet inhibition; Point of care assay; Rapid Platelet Functions Assay

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CORRELATION FUNCTION; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATOCRIT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TIME; UNSTABLE ANGINA PECTORIS;

EID: 0032993922     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008931126871     Document Type: Article

References (19)

1. The EPILOG investigators Platelet glycoprotein IIb/IIIa receptor blockade in low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336: 1689-1696.
2. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind placebo controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention. Circulation 1995;91: 2151-2157.
3. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study investigators. N Engl J Med 1998;338:1498-1505.
4. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade; A randomized placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76-81.
5. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients following coronary stent deployment. Circulation 1997;96:1117-1121.
6. Cannon CP, McCabe CH, Borzak S, et al. and the TIMI 12 investigators. A randomized trial of an oral glycoprotein IIb/IIIa antagonist, sibrafiban, in patients post and acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998;97:340-349.
7. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety and outcomes following prolonged glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multi-center placebo controlled randomized trial. Circulation 1998;98:1268-1278.
8. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-961.
9. Gold HK, Gimple L, Yasuda T, et al. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990;86:651-659.
10. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet GP IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 1991;614:193-213.
11. Smith, JW, Steinhubl SR, Lincoff AM, Coleman J, Li T, Hillman RS, Coller BS. The rapid platelet function assay (RPFA): An automated and quantitative cartridge-based method. Circulation, 1999;99:620-625.
12. Coller BS, Lang D, Scudder LE. A rapid and simple platelet function assay to assess GP IIb/IIIa receptor blockade. Circulation 1997;95:860-867.
13. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti GP IIb/IIIa therapy. Circulation 1997; 96:3860-3866.
14. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antibody FAB-73 in high risk coronary angioplasty. Circulation 1994;90: 1756-1764.
15. Simoons ML, de Boer MJ, van den Brand MJ, et al. For the European Cooperative Study Group. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
16. Steinhubl SR, Kottke-Marchant K, Rosenthal M, Moliterno DJ, Lincoff AM. Diabetics and nondiabetics achieve similar levels of platelet inhibition with abciximab therapy during and following percutaneous revascularization (abstr). Circulation 1998;98:8-767.
17. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-1688.
18. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998;97:5-9.
19. Catella-Lawson F, Kapoor S, Moretti DT, et al. Chronic oral glycoprotein IIb/IIIa antagonism in patients with unstable coronary syndromes: Reduced antiplatelet effect in comparison to patients with stable coronary artery disease (abstr). Circulation 1998;98:I-251.